Abstract | BACKGROUND: This analysis compares the efficacy of risperidone and olanzapine in controlling negative and positive symptoms of chronic psychosis in older patients. METHOD: Post hoc assessments were made in a subset of risperidone-treated (N = 19) and olanzapine-treated (N = 20) older patients (aged 50 to 65 years) from a large international, multicenter, parallel, double-blind, 28-week study of patients aged 18 to 65 years (N = 339) randomly assigned to receive risperidone (4-12 mg/day) or olanzapine (10-20 mg/day). Assessments were made using repeated-measures analysis. RESULTS: At both 8 weeks and 28 weeks, the magnitude of changes in Positive and Negative Syndrome Scale (PANSS) positive symptom subscale scores did not differ between treatment groups (8 weeks: risperidone, -6.5; olanzapine, -6.8, p = .866; 28 weeks: risperidone, -6.5; olanzapine, -7.0; p = .804). However, by the 8-week timepoint, olanzapine had reduced PANSS negative subscale scores significantly more than risperidone (-8.8 vs. -4.9, p = .032). By the 28-week endpoint, olanzapine had continued to maintain significantly greater reduction in baseline-to-endpoint PANSS negative scores (-8.1 vs. -3.5, p = .032) and led to significantly greater reduction in scores on the Scale for the Assessment of Negative Symptoms (SANS) dimensions of affective flattening (-5.2 vs. -0.6, p = .033) and alogia (-3.8 vs. -0.3, p = .007). Patients in the olanzapine treatment group also demonstrated numerically greater reduction of both SANS summary (-3.7 vs. -1.0, p = .078) and SANS composite scores (-14.1 vs. -4.1, p = .075). CONCLUSION:
|
Authors | Peter D Feldman, Christopher J Kaiser, John S Kennedy, Virginia K Sutton, Pierre V Tran, Gary D Tollefson, Fan Zhang, Alan Breier |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 64
Issue 9
Pg. 998-1004
(Sep 2003)
ISSN: 0160-6689 [Print] United States |
PMID | 14628974
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Benzodiazepines
- Pirenzepine
- Risperidone
- Olanzapine
|
Topics |
- Adult
- Age Factors
- Aged
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Benzodiazepines
- Chronic Disease
- Depression
(diagnosis, drug therapy, psychology)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Olanzapine
- Pirenzepine
(adverse effects, analogs & derivatives, therapeutic use)
- Psychiatric Status Rating Scales
- Psychotic Disorders
(diagnosis, drug therapy, psychology)
- Risperidone
(adverse effects, therapeutic use)
- Schizophrenia
(diagnosis, drug therapy)
- Schizophrenic Psychology
- Treatment Outcome
|